Relationships between susceptibility to LAK cell-mediated lysis, conjugate formation and expression of adhesion molecules in B-cell derived non-Hodgkin's lymphomas

被引:7
作者
Chaperot, L [1 ]
Jacob, MC [1 ]
Le Vacon, F [1 ]
Giroux, C [1 ]
Molens, JP [1 ]
Sotto, JJ [1 ]
Bensa, JC [1 ]
Plumas, JL [1 ]
机构
[1] ETS Isere & Savoie, Immunol Lab, F-38701 La Tronche, France
关键词
cytolysis; conjugates; adhesion molecules; non-Hodgkin's lymphoma;
D O I
10.3109/10428199709058339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adoptive immunotherapy with LAK cells has been investigated for the treatment of B-cell-derived lymphomas, but only a few significant tumor regressions were obtained. In order to explain this refractory state, the sensitivity to normal LAK-mediated lysis of 30 non-Hodgkin's lymphoma (NHL) malignant B-cells was determined using flow cytofluorimetry. A large heterogeneity was found, and we report a close correlation (p < 0.001) between the extent of lysis of malignant B-cells and their ability to form conjugates with LAK cells; which is the first step in LAK-mediated cytolysis. The levels of expression of HLA class I molecules, LFA-1 (CD11a/CD18), CD54 and CD58 were also studied and found to be expressed very heterogeneously. CD54 expression on malignant B-cells plays a major role in the initial conjugate formation with LAK cells (p < 0.001), and this was confirmed by inhibition experiments. Our results suggest that a weak expression of CD54 could constitute one mechanism by which NHL tumor B-cells escape natural immune surveillance and resist LAK cells immunotherapies.
引用
收藏
页码:133 / 143
页数:11
相关论文
共 38 条
[1]  
AKELLA R, 1992, EUR J IMMUNOL, V22
[2]  
ALTOMONTE M, 1993, CANCER RES, V53, P3343
[3]   SUSCEPTIBILITY OF ACUTE MYELOGENOUS LEUKEMIA BLASTS TO LYSIS BY LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS AND ITS CLINICAL RELEVANCE [J].
ARCHIMBAUD, E ;
THOMAS, X ;
CAMPOS, L ;
FIERE, D ;
DORE, JF .
LEUKEMIA RESEARCH, 1992, 16 (6-7) :673-680
[4]   RESISTANCE OF DIFFERENT TUMOR-CELLS TO LYSIS BY LYMPHOKINE ACTIVATED KILLER-CELLS CAN BE MEDIATED BY DISTINCT MECHANISMS [J].
BEAN, P ;
MAZUMDER, A .
IMMUNOBIOLOGY, 1992, 185 (01) :63-77
[5]   INTERLEUKIN-2 LYMPHOKINE-ACTIVATED KILLER-CELL THERAPY OF NON-HODGKINS-LYMPHOMA AND HODGKINS-DISEASE [J].
BERNSTEIN, ZP ;
VAICKUS, L ;
FRIEDMAN, N ;
GOLDROSEN, MH ;
WATANABE, H ;
RAHMAN, R ;
ARBUCK, SG ;
SWEENEY, J ;
VESPER, D ;
HENDERSON, ED ;
ZEFFREN, J ;
DENNIN, RA ;
LEVITT, D ;
FOON, KA .
JOURNAL OF IMMUNOTHERAPY, 1991, 10 (02) :141-146
[6]   CHARACTERIZATION OF EFFECTOR-TARGET CONJUGATES FOR CLONED HUMAN NATURAL-KILLER AND HUMAN LYMPHOKINE ACTIVATED KILLER-CELLS BY FLOW-CYTOMETRY [J].
CALLEWAERT, DM ;
RADCLIFF, G ;
WAITE, R ;
LEFEVRE, J ;
POULIK, MD .
CYTOMETRY, 1991, 12 (07) :666-676
[7]   AN IMPROVED DOUBLE FLUORESCENCE FLOW-CYTOMETRY METHOD FOR THE QUANTIFICATION OF KILLER-CELL TARGET-CELL CONJUGATE FORMATION [J].
CAVAREC, L ;
QUILLETMARY, A ;
FRADELIZI, D ;
CONJEAUD, H .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 130 (02) :251-261
[8]   A PHASE-II STUDY OF RECOMBINANT INTERLEUKIN-2 WITH OR WITHOUT RECOMBINANT INTERFERON-BETA IN NON-HODGKINS-LYMPHOMA - A STUDY OF THE CANCER AND LEUKEMIA GROUP-B [J].
DUGGAN, DB ;
SANTARELLI, MT ;
ZAMKOFF, K ;
LICHTMAN, S ;
ELLERTON, J ;
COOPER, R ;
POIESZ, B ;
ANDERSON, JR ;
BLOOMFIELD, CD ;
PETERSON, BA ;
GOTTLIEB, AJ .
JOURNAL OF IMMUNOTHERAPY, 1992, 12 (02) :115-122
[9]   MECHANISMS OF SELECTIVE KILLING OF NEUROBLASTOMA-CELLS BY NATURAL-KILLER-CELLS AND LYMPHOKINE-ACTIVATED KILLER-CELLS - POTENTIAL FOR RESIDUAL DISEASE ERADICATION [J].
FOREMAN, NK ;
RILL, DR ;
COUSTANSMITH, E ;
DOUGLASS, EC ;
BRENNER, MK .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :933-938
[10]   DOWN-REGULATION OF CELL-ADHESION MOLECULES LFA-3 AND ICAM-1 IN EPSTEIN-BARR VIRUS-POSITIVE BURKITTS-LYMPHOMA UNDERLIES TUMOR-CELL ESCAPE FROM VIRUS-SPECIFIC T-CELL SURVEILLANCE [J].
GREGORY, CD ;
MURRAY, RJ ;
EDWARDS, CF ;
RICKINSON, AB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (06) :1811-1824